NZ723369A - Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema - Google Patents

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Info

Publication number
NZ723369A
NZ723369A NZ723369A NZ72336915A NZ723369A NZ 723369 A NZ723369 A NZ 723369A NZ 723369 A NZ723369 A NZ 723369A NZ 72336915 A NZ72336915 A NZ 72336915A NZ 723369 A NZ723369 A NZ 723369A
Authority
NZ
New Zealand
Prior art keywords
antibody
seq
medicament
plasma kallikrein
variable region
Prior art date
Application number
NZ723369A
Other languages
English (en)
Inventor
Daniel Sexton
Christopher Tenhoor
Yung Chyung
Jon Kenniston
Ryan Faucette
Ryan Iarrobino
Joseph Biedenkapp
Burt Adelman
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Priority to NZ761006A priority Critical patent/NZ761006A/en
Publication of NZ723369A publication Critical patent/NZ723369A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ723369A 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema NZ723369A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ761006A NZ761006A (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US201462021397P 2014-07-07 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (1)

Publication Number Publication Date
NZ723369A true NZ723369A (en) 2022-12-23

Family

ID=53681890

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ723369A NZ723369A (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
NZ761006A NZ761006A (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ761006A NZ761006A (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Country Status (18)

Country Link
US (2) US11084884B2 (enExample)
EP (2) EP3096798B1 (enExample)
JP (4) JP6845012B2 (enExample)
KR (4) KR20240049627A (enExample)
CN (2) CN106132442B (enExample)
AU (3) AU2015209481C1 (enExample)
BR (1) BR112016016916B1 (enExample)
CA (1) CA2937329C (enExample)
DK (1) DK3096798T3 (enExample)
EA (1) EA038532B1 (enExample)
ES (1) ES2856076T3 (enExample)
IL (3) IL246864B (enExample)
MX (2) MX387753B (enExample)
NZ (2) NZ723369A (enExample)
PL (1) PL3096798T3 (enExample)
PT (1) PT3096798T (enExample)
WO (1) WO2015112578A1 (enExample)
ZA (2) ZA201605342B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
KR20230054745A (ko) 2013-10-21 2023-04-25 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
JP6657098B2 (ja) 2013-10-21 2020-03-04 ダイアックス コーポレーション 自己免疫疾患の診断と治療
AU2015209481C1 (en) 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
KR102607829B1 (ko) * 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
AU2016340826C1 (en) * 2015-10-19 2023-05-04 Takeda Pharmaceutical Company Limited Immunoassay to detect cleaved high molecular weight kininogen
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
JP7319916B2 (ja) 2016-09-16 2023-08-02 武田薬品工業株式会社 遺伝性血管性浮腫のｒｎａバイオマーカー
CN109716138B (zh) * 2016-09-16 2023-10-03 武田药品工业株式会社 用于接触活化系统相关的疾病的蛋白生物标记
KR20200067195A (ko) * 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105419A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
WO2019105437A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105414A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
KR102617947B1 (ko) 2017-12-29 2023-12-27 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 접합체와 제조 및 그 용도
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
WO2020063198A1 (zh) 2018-09-30 2020-04-02 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
EP3903830A4 (en) 2018-12-28 2023-04-26 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
US20200317815A1 (en) * 2019-03-14 2020-10-08 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
AU2020280438B2 (en) 2019-05-22 2025-03-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP3992290A4 (en) * 2019-05-24 2023-11-15 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
WO2021202948A2 (en) * 2020-04-04 2021-10-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1987005396A1 (en) 1986-03-03 1987-09-11 Brigham And Women's Hospital A method for evaluating nephrotoxicity
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
AU2003243394B2 (en) 2002-06-07 2008-06-12 Takeda Pharmaceutical Company Limited Prevention and reduction of blood loss
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
WO2005075665A2 (en) 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
PT2374472T (pt) 2006-03-16 2018-08-08 Dyax Corp Composições e métodos para o tratamento de afeções oftalmológicas
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
CN101801406B (zh) * 2007-07-20 2014-04-23 代阿麦迪卡股份有限公司 用于治疗淀粉样蛋白相关疾病的组织激肽释放酶
AU2008288772A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
EP2313109A2 (en) 2008-07-02 2011-04-27 Emergent Product Development Seattle, LLC Il6 immunotherapeutics
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
KR102502293B1 (ko) * 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
CA3051418C (en) 2011-05-02 2021-05-18 Millennium Pharmaceuticals, Inc. Methods of treating inflammatory bowel disease
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
TR201904638T4 (tr) 2013-01-20 2019-04-22 Dyax Corp pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20230054745A (ko) 2013-10-21 2023-04-25 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
AU2015209481C1 (en) 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
KR102607829B1 (ko) 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
WO2018053247A1 (en) * 2016-09-16 2018-03-22 Dyax Corp. Metabolite biomarkers for diseases associated with the contact activation system
EP3678551B1 (en) 2017-09-05 2023-06-28 Sanolla Ltd Electronic stethoscope with enhanced features
AU2019328324B2 (en) 2018-08-30 2025-06-19 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US20200317815A1 (en) 2019-03-14 2020-10-08 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
MX2022008649A (es) 2020-01-13 2022-09-23 Takeda Pharmaceuticals Co Inhibidores de calicreina plasmatica y sus usos para tratar episodios de angioedema hereditario pediatrico.

Also Published As

Publication number Publication date
CN106132442A (zh) 2016-11-16
JP6845012B2 (ja) 2021-03-17
JP2024170495A (ja) 2024-12-10
US11084884B2 (en) 2021-08-10
KR102903403B1 (ko) 2025-12-24
US12384854B2 (en) 2025-08-12
KR20240049627A (ko) 2024-04-16
JP2017503820A (ja) 2017-02-02
EP3848057B1 (en) 2025-12-10
ZA202004653B (en) 2022-01-26
EA038532B1 (ru) 2021-09-10
AU2015209481B2 (en) 2020-07-30
EP3096798B1 (en) 2020-11-25
KR20240033156A (ko) 2024-03-12
EP3848057A1 (en) 2021-07-14
CA2937329A1 (en) 2015-07-30
BR112016016916A2 (pt) 2018-01-23
PL3096798T3 (pl) 2021-07-26
IL263669B (en) 2020-10-29
US20170002094A1 (en) 2017-01-05
MX2021013665A (es) 2021-12-10
US20210087293A1 (en) 2021-03-25
AU2015209481C1 (en) 2020-10-29
AU2015209481A1 (en) 2016-08-25
JP2020002171A (ja) 2020-01-09
IL278062B (en) 2022-06-01
JP2023015087A (ja) 2023-01-31
IL278062A (en) 2020-11-30
BR112016016916A8 (pt) 2018-05-02
JP7164502B2 (ja) 2022-11-01
ZA201605342B (en) 2020-11-25
ES2856076T3 (es) 2021-09-27
WO2015112578A1 (en) 2015-07-30
AU2024203436A1 (en) 2024-06-13
CA2937329C (en) 2022-05-31
IL263669A (en) 2019-01-31
EP3096798A1 (en) 2016-11-30
BR112016016916B1 (pt) 2023-12-19
KR20220107077A (ko) 2022-08-01
KR20160122169A (ko) 2016-10-21
MX387753B (es) 2025-03-18
DK3096798T3 (da) 2021-03-01
MX2016009428A (es) 2017-04-13
IL246864B (en) 2018-12-31
EP3096798A4 (en) 2017-08-23
CN106132442B (zh) 2023-07-14
AU2020244370A1 (en) 2020-10-29
PT3096798T (pt) 2021-02-25
EA201691470A1 (ru) 2016-12-30
KR102424183B1 (ko) 2022-07-26
CN116585468A (zh) 2023-08-15
NZ761006A (en) 2023-04-28
AU2020244370B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
NZ723369A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PH12021550023A1 (en) Humanized anti-tau antibodies
MX2014001374A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2014001370A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
WO2018075857A8 (en) Novel cd47 monoclonal antibodies and uses thereof
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
CY1121249T1 (el) Αντισωμα εναντι του ειδικου προστατικου αντιγονου βλαστικου κυτταρου και χρησεις αυτου
NZ606095A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
AR079903A1 (es) Formulacion de anticuerpo y regimenes terapeuticos. envase farmaceutico. kit.
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
BR112014002613A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método
EA201991704A2 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
JP2020502198A5 (enExample)

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210702

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2025 BY ANAQUA SERVICES

Effective date: 20231220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 JAN 2026 BY ANAQUA SERVICES

Effective date: 20241219